SBIR-STTR Award

Immunohistochemical Study of Oral Dysplasia
Award last edited on: 1/28/2022

Sponsored Program
SBIR
Awarding Agency
NIH : NIDCR
Total Award Amount
$175,388
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
Raymond Ranken

Company Information

Biocircuits Corporation

1234 Chesapeake Terrace
Sunnyvale, CA 94089
   (408) 745-1961
   N/A
   N/A
Location: Single
Congr. District: 17
County: Santa Clara

Phase I

Contract Number: 1R43DE007539-01
Start Date: 2/1/1986    Completed: 7/31/1986
Phase I year
1986
Phase I Amount
$49,500
There are no sensitive in vitro diagnostic tests for the detection of oral dysplasia or carcinoma. Although frank malignancies are more readily diagnosed, there are inconsistencies in the categorizing and diagnosis of what are generally termed premalignant conditions. Immunodiagnosis may prove superior to the current method of subjective evaluation of cellular morphology, not only in terms of speed and sensitivity, but also in objectivity. The development of a cocktail of highly associated squamous cell carcinoma monoclonal antibodies to be used as an immunohistochemical reagent will contribute to the effective diagnosis of oral disease. The long range goal of the research is to produce an immunohistochemical reagent which will: 1) Detect all stages of squamous cell carcinoma as well as all cells within the tumor mass, and 2) Will detect premalignant lesions. Those monoclonals selected in Phase I will be evaluated in a large scale clinical study in Phase II.

Phase II

Contract Number: 2R44DE007539-02
Start Date: 2/1/1986    Completed: 1/31/1989
Phase II year
1987
Phase II Amount
$125,888
There are no sensitive in vitro diagnostic tests for the detection of oral dysplasia or carcinoma. Although invasive epithelial malignancies are quite readily diagnosed, there are inconsistencies in the categorizing and diagnosis of what are generally termed dyplasias and other premalignant conditions. Transformation potential of what might appear to be normal or clear margins remains quite questionable. Immunodiagnosis may prove superior to the current method of subjective evaluation of cellular morphology, not only in terms of speed and sensitivity, but also in objectivity. The development of cocktail of highly associated squamous cell carcinoma monoclonal antibodies to be used as an immunohistochemical reagent will contribute to the effective diagnosis of oral disease. The long range goal of the research is to produce an immunohistochemical reagent which will: 1) Detect all stages of squamous cell carcinoma as well as all cells associated with the tumor mass, and 2) Will detect premalignant lesions. Those monoclonals selected in Phase I will be evaluated in a large scale double blind clinical study in Phase II involving three centers.